Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Feb 15, 2019 11:17 AM IST | Source: PTI

Alembic Pharma gets USFDA nod for ophthalmic solution

The approved product is therapeutically equivalent to the reference listed drug product Vigamox Ophthalmic Solution USP, 0.5 per cent, of Novartis Pharmaceuticals Corporation.

Representative Image
Representative Image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Moxifloxacin Ophthalmic Solution, used for treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.

The approved product is therapeutically equivalent to the reference listed drug product Vigamox Ophthalmic Solution USP, 0.5 per cent, of Novartis Pharmaceuticals Corporation.

"The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Moxifloxacin Ophthalmic Solution USP, 0.5 per cent," Alembic Pharmaceuticals said in a BSE filing.

Close

Quoting IQVIA sales data, the company said, Moxifloxacin Ophthalmic Solution USP, 0.5 per cent, has an estimated market size of USD 68 million for 12 months, ending December 2018.

The company said it now has a total of 86 ANDA approvals from the USFDA.

Shares of Alembic Pharmaceuticals were trading at Rs 539.90 apiece, up 0.89 per cent, on the BSE.

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Feb 15, 2019 11:15 am
Sections
Follow us on